NCT03477539 · OUTCOME

Antibody-dependent Cellular Phagocytosis and Antibody-dependent Cell-mediated Cytotoxicity

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma · Source last updated 2026-05-05

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to cycle 18/16 months of treatment

What was measured

These will be assessed as continuous variables and their mutual change over time as assessed on the pre-specified time points will be correlated with response category to the treatment.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: These will be assessed as continuous variables and their mutual change over time as assessed on the pre-specified time points will be correlated with response category to the treatment.
reporting Status: NOT_POSTED
time Frame: Up to cycle 18/16 months of treatment
title: Antibody-dependent Cellular Phagocytosis and Antibody-dependent Cell-mediated Cytotoxicity
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice